Quote:

---

When used to treat COVID-19 for the authorized population, the known and potential benefits of these antibodies outweigh the known and potential risks. There are no adequate, approved and available alternative treatments to bamlanivimab and etesevimab administered together for the authorized population.

---

I've never wanted to punch a press release in the nose so hard before.

Just admit it, it's because it's Eli Lilly, and nothing else.